Renal Cell Carcinoma

Health-Related QoL Data Stand Out in Support of Nivolumab Plus Cabozantinib in Advanced RCC

October 19, 2020

In an interview with Targeted Oncology, Bradley McGregor, MD, discussed the findings from the CheckMate-9ER study of nivolumab and cabozantinib as treatment of patients with advanced renal cell carcinoma, as well as the health-related QoL data supporting the use of this combination.

Combination Therapy Continues to Demonstrate Efficacy in Advanced Renal Cell Carcinoma

October 13, 2020

In an interview with Targeted Oncology, Rana R. McKay, MD, discussed the findings from the CheckMate-9ER study of nivolumab plus cabozantinib in patients with advanced or metastatic renal cell carcinoma who had not been previously treated.

Deferred Cytoreductive Nephrectomy Plus Sunitinib Bests Immediate Surgery in RCC

September 22, 2020

In a post hoc analysis of the randomized phase 3 SURTIME trial of patients with metastatic renal cell carcinoma, early treatment with sunitinib demonstrated better control over the disease as well as detection of progression before planned cytoreductive nephrectomy.

A 58-Year-Old Man With Advanced Renal Cell Carcinoma

September 22, 2020

Robert Alter, MD, of John Theurer Cancer Center, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.

Cabozantinib Doublet Achieves Early Clinical Activity in Advanced ccRCC

September 21, 2020

Patients with advanced clear cell renal cell carcinoma treated with cabozantinib in combination with atezolizumab in the phase 1b COSMIC-021 study, had promising clinical activity, according to results from the study presented during the 2020 European Society of Medical Oncology Virtual Congress.

Molecularly-Guided Therapy Improves Responses in mRCC

September 21, 2020

The use of molecularly-directed frontline therapy enriched responses in patients with metastatic clear cell renal cell carcinoma, demonstrating clinical evidence to support further use, according to findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial.

Durable Benefit Observed at 4 Years With Nivolumab Plus Ipilimumab in Advanced RCC

September 19, 2020

At 4 years of follow-up, nivolumab and ipilimumab in combination as first-line therapy of advanced renal cell carcinoma demonstrated durable benefit versus sunitinib, according to research presented at the 2020 ESMO Virtual Congress.